Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Lawrence Ginsberg, MD

President
Red Oak Psychiatry Associates, P. A.
Member of the Healthcare Council

Lawrence Ginsberg, MD, is President and CEO of Red Oak Psychiatry Associates, PA, a multidisciplinary mental health group in Houston, Texas. Dr. Ginsberg's research interests include psychopharmacology, addiction medicine, and forensic psychiatry. His areas of clinical expertise are attention deficit hyperactivity disorder (ADHD) and bipolar disorder in both children and adults, as well as generalized anxiety disorder and panic disorders. Dr. Ginsberg consults for over 20 pharmaceutical companies and has been an investigator on numerous drug trials for anxiety, bipolar disorder, and ADHD. (This is me - Update Profile)


Employment History
1991 - present President
Red Oak Psychiatry Associates, P. A.
1985 - 1990 Physician
Post Oak Psychiatry Assoc.

GLG Study Groups with Lawrence Ginsberg, MD(?)

View All Study Groups with Lawrence Ginsberg, MD

GLG NewsSM Analyses by Lawrence Ginsberg, MD(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Vanda"s Iloperidone: Lemonade or Lemon | 10-11-2007
Analysis of: Vanda Pharmaceuticals Submits Iloperidone New Drug Application | www.pipelinereview.com
Author: Lawrence Ginsberg, MD, President, Red Oak Psychiatry Associates, P. A.

1. Iloperidone has demonstrated efficacy in treating positive and negative symptoms of schizophrenia and also has a favorable safety profile. 2. Vanda has utilized pharmacogenetic studies to identify a group of schizophrenic patients that will benefit from this agent that binds to a number of serotonin...

DOV 21,947: A Triple Reuptake Inhibitor With a Favorable Metabolic Profile | 10-08-2007
Analysis of: DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug Compliant Subjects in Phase Ib Clinical Study | www.medicalnewstoday.com
Author: Lawrence Ginsberg, MD, President, Red Oak Psychiatry Associates, P. A.

1. DOV 21,947 in a phase Ib study produced a statistically significant reduction in plasma triglyceride levels, body weight, and Body Mass Index (BMI). 2. This compound is believed to not only manage depression but also impact weight gain. 3. A phase II study of DOV 21,947 is being delayed until the...

Shire Takes Proactive Stance Regarding Daytrana Skin Patches | 09-18-2007
Analysis of: Shire withdraws some ADHD skin patches | www.reuters.com
Author: Lawrence Ginsberg, MD, President, Red Oak Psychiatry Associates, P. A.

1. Shire has withdrawn patches that had defective patch liners. 2. This defect is not related to safety or efficacy issues. 3. The cost to Shire is less than $10 million.

New Potentially Effective Antidepressants to be Marketed by a Potentially Effective Alliance | 09-12-2007
Analysis of: Lundbeck and Takeda form Alliance to Develop and Commercialize a Portfolio of Novel Compounds in the US and Japan for the Treatment of Mood and Anxiety Disorders | www.pipelinereview.com
Author: Lawrence Ginsberg, MD, President, Red Oak Psychiatry Associates, P. A.

1. Lu AA21004 and Lu AA24530 are two compounds with a great deal of potential and will be co-marketed jointly by Takeda and Lundbeck. 2. Lu AA21004 is the more advanced of the compounds and is currently in phase II development for the treatment of major depression. 3. The compounds potentially address...

View All GLG News SM Analyses by Lawrence Ginsberg, MD

GLG InstituteSM Seminars with Lawrence Ginsberg, MD(?)

 
Lawrence Ginsberg, MD has not participated in any GLGi Seminars.
View all GLG InstituteSM Seminars in Healthcare

Request a project with Lawrence Ginsberg, MD









Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-08-28T21:45:18.233